

A C E N T U R Y O F

trust



GSK

GlaxoSmithKline Pharmaceuticals Limited

A CENTURY OF
trust



▲ Glaxo's first factory at Worli, Bombay (now Mumbai), Maharashtra

1

0

0

years of
trust



► GSK India's present-day manufacturing factory located in Nashik, Maharashtra



GSK's

history spans three centuries
and multiple continents
around the world.

In the vibrant streets of London, there existed a
modest pharmacy that opened its doors to the
world. From its humble beginnings at the Plough
Court Pharmacy in 1715, few could foresee the
remarkable legacy that would transcend borders
and touch

countless lives



▲ Glaxo in London

Glaxo's first
research team ▶



◀ Plough Court
Pharmacy

globally

In India's healthcare story, GSK emerges as a beacon of hope, standing strong for a century. Throughout our journey, we've achieved significant milestones, from pioneering breakthroughs to life-saving medicines and vaccines, impacting countless lives across the nation.

Yet, our story isn't solely about accomplishments. It's about our people within GSK India—be it our sales representatives, executives, or patients—who collectively shape and define what GSK India represents today.

Together we
have driven

GSK India's



mission ahead



As we traverse through the chapters of this remarkable journey, we remain even more committed to deliver on our purpose to positively impact patient's lives and continue to build trust established over the century. Thus igniting the aspirations of generations to come.

Snippets of a Remarkable Journey



Message from the Chairpersons



A century of research and formulating healing and preventive remedies is a noteworthy and remarkable chunk of time, energy and perseverance. I commend all those who made this possible at GSK; one of the progressive pharmaceutical entities now a 100 years in the making.

Personally, I am humbled by this service to humanity and proud to have been a part of this curative journey, healing millions across India and providing essential drugs so critical for care and sustenance.

GSK is perceived as a safe and coveted brand in the healthcare space and I foresee many more innovations in the GSK clutch of medicines.

My congratulations at this pivotal juncture in time.

D S Parekh
1998-2019



Our confidence and capabilities are backed by 100 years of trust. We are dedicated to upholding this legacy by consistently introducing new products from GSK’s global portfolio. Our commitment ensures that we continually meet the evolving needs of our customers and patients. I would like to thank our people for their contribution and express my gratitude towards all our stakeholders, including doctors, vendors, Contract Manufacturing Organisations (CMOs), hospitals, and shareholders for their unwavering faith in our vision and purpose as we step into our centenary year in November 2024.

R.S. Karnad
2019 - Present

The Pathway to a Century of Trust



Message from the Managing Director



With Innovation as our focus, we have enormous opportunity to prevent and change the course of diseases for millions of people in India.

Signposts for the future

GSK India is a forward-looking company with an exciting future — a biopharma powerhouse, transcending geographies, cultures and nationalities. We are mindful of our global quest to improve the quality of human life for future generations.

Yet, this could only have been achieved by building on the solid foundations of the companies that have led to the creation of today’s GSK.

GSK’s 100-year journey in India has drawn inspiration from the passion and commitment of our people. For 100 years we have earned the trust of generations by consistently delivering high-quality medicines and vaccines.

It is a testament of our belief that prevention is the best medicine – with Innovation as our focus, we have enormous opportunity to prevent and change the course of diseases for millions of people in India.

This coffee table book highlights some of these past achievements. They are notable events that will lead to further success for GSK India to get ahead of disease, together. We remain focused on delivering this potential - and more - at continued pace for patients, for shareholders and for our people.

B. Akshikar

GSK India's

Managing Directors Leading the Way

Before we dive into our story, let's give a shout-out to our amazing leaders who have steered the ship at GSK India. Meet the Managing Directors who have been the driving force behind GSK India's remarkable 100-year journey. Each one brought their own special vision to the table, leaving an indelible mark on GSK India's past and leading the way for its future.



I MacKinnon
1968-71



D J R Farrant
1971-73



G J Medley
1973-78



J S Khambata
1978 -90



H Dhanrajgir
1990-94



V Thyagarajan
1994-96 & 2001-02



H R Khusrokhhan
1996-2000



S Kalyanasundaram
2003-2006



H B Joshipura
2007-2015



A Vaidheesh
2015-2020



S Venkatesh
2020-2022



B Akshikar
2022-Present

Evolving with time, rooted in purpose



Glaxo Laboratories began as a subsidiary company but quickly outpaced its parent in sales and product range. The “Glaxo” logo, with its swirling script and grand loops, spoke of timeless elegance and a storied legacy.

Glindia

Glaxo Laboratories became Glindia Limited in 1987. It was written in bold, orange letters, positioned against a plain background. The text had a clear and modern font that conveyed a sense of contemporary professionalism.

Glaxo

In 1989, Glindia became Glaxo India Limited, the blue logo was simple highlighting the name of the company.



GlaxoSmithKline

Following the merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals Limited, the company rebranded as GlaxoSmithKline Pharmaceuticals Limited in the year 2001. The new logo, characterised by bold orange lowercase text enclosed within an oval shape, conveyed an inviting and warm aura.



The GSK logo, introduced in 2013, marked the next iteration. It maintained the oval shape but featured a darker shade of orange, reflecting a move towards modernity and sophistication.

GSK

Marking a significant departure from its predecessors, this logo saw the transformation of GlaxoSmithKline into GSK in the year 2022, with all-capital letters standing alone, projecting strength and resilience. Each curve on the logo evokes the highly adaptable nature of the human immune system, serving as a reminder to continually evolve and adapt.

Our History




At the beginning of the century, when Joseph Nathan & Co, first made their wonderful dried milk for babies, they decided to give it a name ‘Lacto’ from Latin, lactis meaning milk. But the name was not acceptable to the Registration Office. The Company then hit upon the word ‘Glacto’, derived from galactose, one of the milk sugars. At this stage, someone suggested that ‘Glaxo’ would be more pleasant to the ear. Thus, the new name – that eventually became a household word – was born.

1920s

Seeds of Compassion

In the lively mosaic of Indian life, a small yet mighty dream began. In 1924, we as H.J. Foster & Co. Limited, later to be known as Glaxo Laboratories, began our journey that would shape the landscape of Indian healthcare for generations to come.



We introduced formula milk in India. Glaxo stepping into the world of baby food was a move that was straight from the heart. We identified the nutritional needs of infants and the lack of reliable brands. So we worked to fill this gap.

With each spoonful savoured, it became more than just nourishment—it became a symbol of hope, a reminder that even in the face of adversity, the nation's youngest citizens would always have a steadfast ally in their journey towards growth and vitality.



From the Archives

Glaxo Products played a minor role in Foster's business early on. But fast forward to the early '30s, the all-important products were those bearing the Glaxo trade mark. Fosters eventually became a wholly-owned subsidiary of Glaxo Laboratories Ltd. in the UK.



1930s

Nurturing Growth

As the 1930s rolled in, we stepped into a new chapter. The Worli factory in Bombay (now Mumbai) became our symbol of care towards Indians, making sure essential medicines were always available for those who needed them.



We also established our base in Madras (now Chennai) and Calcutta (now Kolkata), showcasing our commitment to growth. This move laid the foundation for our future success, demonstrating Glaxo's dedication to reach new heights.

Our vision went beyond factory walls. By setting up production closer to home, we made sure Indian families had a lifeline when it came to health—a bond that has stood strong through adversity.



Glaxo's legacy companies and their people have established pioneering standards in sales and marketing practices



Miniature Power House in Worli, Bombay





Fact Flash

While the first Glaxo structure at Worli was established in 1938, it was decided that a Provident Fund scheme should be introduced for all members of the Staff. This decision underscored our commitment to the long-term welfare and financial security of our employees.

1940s

Pioneering hope in times of need

During critical periods, Glaxo leveraged its pharmaceutical expertise to provide essential medicines and supplies to meet urgent public health needs.



▲ Women have been indispensable to our workforce, making their participation and Diversity, Equity & Inclusion inherent to our legacy



A notable achievement was our production of Penicillin, a groundbreaking antibiotic crucial for treating infections. Recognising the pressing demand for this life-saving medication, we significantly ramped up production to ensure an adequate supply for hospitals and healthcare facilities.

In addition to Penicillin, we manufactured a range of other important medicines and medical supplies, including pain relievers and antiseptics, which played a key role in alleviating suffering and improving health outcomes.

Our unwavering commitment to serving communities highlights our dedication to advancing global health, even amidst challenging circumstances.

▲ In 1947, Glaxo established its corporate office and factory in Worli, Bombay, where GSK's India head office remains located to this day

1950s

A Journey of Discovery

In the 1950s, ensuring drug security in India was tough, with regulatory challenges and limited access to quality medicines. However, Glaxo stepped up to this challenge and played a key role in contributing to nation-building endeavours.

1951 was the year when the present Medical Centre, with its up-to-date equipment, including X-ray apparatus and Pathological Laboratory, was established. Sister Wray, B. P. N. A., joined us in June of this year. Free medical facilities had, however, been available to the staff and their families since the beginning of 1943, with Dr. J. C. Patel, Ph. D., M. D., M.R.C.P., officiating in a small, sparsely-furnished room in Building 38. Dr. Eric de Mello, M. D., (see picture) joined us as Medical Officer in June 1947. By 1954 staff increases necessitated the appointment of a second Medical Officer, Dr. A. Mascarenhas, M. B., B. S.

10



The Company changed its name from H. J. Foster & Co. to Glaxo Laboratories (India) Limited in 1950




Through our commitment to maintain quality control and adherence to regulatory standards, we bolstered trust among healthcare professionals and consumers, laying the groundwork for a more secure healthcare landscape in India.

Throughout the years, we have consistently aligned with the evolving needs of our nation, emerging as a trusted partner in India's quest for improved health and well-being.

In the 1950s, we enhanced our research and development by producing India specific medicines like Eltroxin tablets, which was the need of the hour for patients diagnosed with Thyroid.



◀ Eltroxin tablets



Start of the secondary manufacturing of products at Worli factory by filling of Crystalline Penicillin in January 1950



▲ In 1953, Sir Alexander Fleming who discovered Penicillin in 1928, paid a visit to Glaxo's Bombay factory



1953 saw Calcutta Office established in their present premises at Kidderpore. The first branch to come into being, in 1926, Calcutta were also the first to have their own building. This picture, taken in December 1952, shows from right to left Mr. Gwilt, Mr. H. W. Palmer (on a visit from London) and Mr. Fraser-Allen inspecting the new Office shortly before its completion.

Nycil powder introduced in 1951, provided much-needed relief for individuals with prickly heat during scorching Indian summers.



1960s

Decade of Breakthroughs

This decade began with Glaxo setting up modern manufacturing facilities in Aligarh, Uttar Pradesh, and Thana (now Thane), Maharashtra.

In Aligarh, amid the bustling activity, we boosted the production of baby foods in India, recognising the importance of early nutrition.



Glaxo Milk drying factory in Aligarh



Thana (now Thane) factory



Meanwhile, our laboratories in Thana were buzzing with excitement as our scientists worked on groundbreaking medicines that would revolutionise healthcare in India.



A vintage Glaxo advertisement on an Indian street

Established in 1962, the Thana factory produced Vitamin A, corticosteroids, calcium sennosides, and beta-ionone from Indian lemongrass. It also featured a Medical Centre and Staff Housing Colony, inaugurated by Mr. Y. B. Chavan, then Chief Minister of Maharashtra.

In 1968, we became a limited company and also introduced animal health products to the Indian market.

The following year, we proudly became a founding member of the Organisation of Pharmaceutical Producers of India (OPPI). Through OPPI's advocacy efforts, we played a key role in shaping the future of healthcare in India.

As the 1960s drew to a close, we celebrated a notable achievement: our listing of shares on the Indian Stock Exchange, showcasing our commitment to transparency and accountability.



Introduction of Animal health products



Legacy Highlight

Glaxo has been consistently meeting its tax obligations. By adhering to tax regulations, Glaxo has not only fulfilled its civic duties but also played a crucial role in nation building.




UK High Commissioner visits Glaxo Bombay



Acquisition and amalgamation of British Drug House with the Company



Product testing plant, Thana



The Fine Chemical Factory, Thana

1970s

Resilient amidst adversity

In the challenging 1970s, we faced a tough test in India. The drug price control order impacted over 25% of our portfolio.

Amidst the challenges, our resilience ensured that we remained steadfast in fulfilling our promise and commitment to patients in India.

Glaxo remained dedicated to delivering essential medicines at equitable prices, always placing quality at the forefront. Through innovation, we demonstrated our unwavering dedication to enhancing the lives of patients throughout India.



Another significant move in the 1970s was the introduction of the Ventorlin inhaler, revolutionising respiratory care and offering hope to those with breathing difficulties. Additionally, we introduced products such as Cobadex capsules.



Fact Flash

We pioneered medical detailing in India by introducing the concept of detailing aids, to promote pharmaceutical products to healthcare professionals (HCPs).



▲ Packshot of Ventorlin Inhaler



▲ Glaxo's leading products during the decade

1980s

Going from Strength to Strength

In the early 1980s, continuing its commitment to patients in the country, Glaxo set up a new manufacturing facility in Nashik, Maharashtra.



▲ Manufacturing facility, Nashik

Our contribution to public health was fortified with the launch of Engerix B in 1982. This wasn't just another vaccine; it was a shield against a silent threat looming over countless lives—Hepatitis B.



▲ Launch of Augmentin, a leading brand showcasing our legacy of innovation

Overtime, Phexin and Neocef became symbols of reassurance, providing relief to people struggling with infections. These medicines effectively fought off bacteria, helping patients recover faster.

Moreover, with Betnelan Forte and Betnesol Forte, corticosteroids renowned for their anti-inflammatory properties, we offered strength and comfort to individuals battling various ailments. These medications reduced inflammation, alleviating symptoms and promoting healing in patients with conditions like allergies, asthma, and autoimmune disorders.



▲ Betnesol Forte

Later on, Supacef, an injectable antibiotic, was introduced. With each injection administered, we reiterated our dedication to enhancing healthcare accessibility



▲ In 1987, Glaxo Laboratories Limited rebranded as Glindia Limited, and in 1989, Glindia Limited changed its name to Glaxo India Limited



▲ In 1988, our vaccine innovation legacy from Rixensart, Belgium, led to the launch of Engerix B in India. This marked our leadership in the private vaccines market, shifting healthcare practices in the country




▲ In 1985, the Ankleshwar factory was inaugurated, establishing manufacturing facilities for Active Pharmaceutical Ingredients (APIs)

The 1990s was a Dynamic Era

We continued in our quest for groundbreaking solutions tailored to address India's unique healthcare challenges.

New solutions like Salbutamol Inhaler for the treatment of asthma, Ceftum and Supacef tablets for infections and Tenovate, a potent corticosteroids ointment were introduced.



In 1990, Flutivate, a breakthrough topical steroid was launched. It marked a new frontier in dermatological care, promising relief from various inflammatory skin conditions such as eczema and psoriasis. Trusted by dermatologists and patients alike, Flutivate continues to be a go-to solution for managing troublesome skin conditions.

In 1994, Glaxo sold its Family Products Division to H J Heinz India Pvt. Ltd., marking a strategic move in our journey.



◀ Complan sold to H J Heinz India Pvt. Ltd.

In 1996, we expanded our horizons by acquiring the Biddle Sawyer Group of Companies, further strengthening our capabilities.

In 1999, we celebrated a significant milestone as Glaxo completed 75 years in the country and was honoured as India's most respected company by Businessworld Magazine.



Fact Flash

GlaxoWellcome

In 1995 the Wellcome Trust sold shares to Glaxo plc, forming the world's largest pharmaceutical company, Glaxo Wellcome plc. In India, the merger of the two Indian entities was completed in 2004.



▲ In 1993, Mother Teresa graced the Worli office with her presence

2000-2010

Navigating new Horizons


In the landmark year of the new millennium, our organisation achieved a significant milestone with the announcement on January 17, 2000, of the merger between Glaxo Wellcome and SmithKline Beecham. Following regulatory and shareholder approval, the merger was finalised on December 27, 2000. Throughout the year, our dedicated team diligently maintained momentum across both businesses, successfully orchestrating the integration of these two renowned companies with esteemed pharmaceutical legacies. This merger marked a pivotal moment in the pharmaceutical industry, positioning our organisation for enhanced innovation and global impact.



▲ Glaxo Wellcome and SmithKline Beecham Pharmaceuticals successfully merged, leading to the company's name change to GlaxoSmithKline Pharmaceuticals

In 2004, Burroughs Wellcome India merged with GSK India, following the global merger of their parent companies.

Following its introduction in 2010, Calpol quickly ascended to become a beloved staple in India's pharmaceutical market, securing the top position.




▲ Launch of Seretide, an inhaler and accuhaler to treat and manage Asthma

In a noteworthy initiative, our Nashik facility committed itself to the production of Albendazole, contributing to the battle against Lymphatic Filariasis in partnership with World Health Organisation (WHO).



With India at our core, we embarked on a bold mission, pledging over \$1 billion to reach 40% of the world's affected population. Through tireless awareness campaigns and treatments, we managed to bring hope to communities nationwide, proving that united efforts can conquer even the toughest health challenges.



2010 to Present

Innovating for tomorrow

In the ever-evolving world of healthcare, we embarked on an exciting journey filled with innovation and progress with the introduction of **Infanrix Hexa** at the dawn of the decade. This marked a giant leap forward in paediatric vaccination, providing protection against six diseases—diphtheria, tetanus, pertussis, Hib, hepatitis B, and polio.



In 2018, the introduction of a robotic assembly line revolutionised the manufacturing process for **Betnovate**.

As time went by, in 2019

we launched **Nucala**, revolutionising respiratory treatment and reshaping the management of respiratory conditions.



This launch paved the way for additional patient-centered products from our global pipeline, offering further healthcare advancements tailored to patient requirements.



Fast forward to 2021

we unveiled another milestone with the launch of **Trelegy Ellipta**, India's first single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. This innovative therapy, designed for daily use, aimed to bring relief to more COPD patients across India.

In 2023

we introduced **Shingrix** in India, a vaccine for prevention of Shingles (Herpes Zoster) and post-herpetic neuralgia (PHN) in adults aged 50 and above, creating a new category in adult immunisation.

We are also modernising our General Medicines portfolio - **Calpol 650**, leading the paracetamol market in the Indian Pharmaceutical Market (IPM), is now **Calpol 650+** with 'Optizorb Formulation,' promoting faster molecule dissolution.

As part of the strategic shift, newer ways of working have been developed to inculcate Omnichannel strategies as the new normal across all marketing strategies - to seamlessly connect all channels, platforms, and content.



Today - Beyond boundaries

GSK Global Capability Centre (GCC), India was established at Bengaluru in 2021 which shines as a hub of innovation and progress in the pharmaceutical sector, like a modern-day powerhouse of industry excellence.

GCC R&D team capabilities include:



- ▶ Clinical Operations
- ▶ Biostatistics
- ▶ Regulatory Affairs
- ▶ Global Safety
- ▶ Pharmacovigilance (Agreements and Safety Clauses)
- ▶ Clinical Trials (Publication and Transparency)

The presence of these diverse R&D teams showcases GSK's commitment to quality, collaboration and innovation in the pharmaceutical industry.



GSK India's Global Capability Center (GCC)

This LEED Platinum certified smart working office is a strategic arm of GSK that was set up to house diverse talent to build differentiated capabilities for future global impact. GCC currently hosts employees

who are part of various global business operations with capabilities to support longterm success of Global Functions and Pharma R&D. The center is home to multiple teams of talented people.



Bringing together science, technology and talent to deliver impact



#AheadTogether

We are a focused biopharma company with strong momentum and big ambitions. Our culture of being ambitious for patients, accountable for impact, and doing the right thing drives our leadership.

For a century, we have been an integral part of India's 'Make in India' story, laying the groundwork for a workplace culture fuelled by relentless pursuit of excellence.

At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Our robust manufacturing capabilities touch millions of lives underscoring our unwavering commitment to global health. Our legacy isn't just a static concept; it's a dynamic force propelling us forward, shaping a future where innovation and impact intersect to create a healthier world.

Together, let's continue this journey, weaving a tapestry of innovation, impact, and inclusivity.





GlaxoSmithKline Pharmaceuticals Limited

Registered office address

GSK House, 252, Dr. Annie Besant Road, Worli,
Mumbai - 400 030, Maharashtra, India

Tel: 022-2495 9595

www.gsk-india.com